Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Haematologica. 2017 Aug 03;:
Authors: de Weerdt I, Koopmans SM, Kater AP, van Gelder M
Abstract
The use of novel B cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenstroms macroglobulinemia. Ibrutinib, the first-in-class inhibitor or Bruton's tyrosine kinase, and idelalisib, the first-in-class inhibitor of phosphatidylinositol 3-kinase δ have recently been approved for several indolent B cell malignancies. These drugs especially foresee in previously unmet needs for patients with relapsed or refractory disease, high-risk cytogenetic or molecular abnormalities or with comorbidities. Treatment with ibrutinib and idelalisib is generally well tolerated, even in elderly patients. However, their use may come with toxicities that are distinct from the side effects of immunochemotherapy. In this review we discuss the reported most common and/or clinically most relevant adverse events associated with these B cell receptor inhibitors, with special emphasis to recommendations of their management.
PMID: 28775119 [PubMed - as supplied by publisher]

Source: Haematologica - August 3, 2017 Category: Hematology Authors: de Weerdt I, Koopmans SM, Kater AP, van Gelder M Tags: Haematologica Source Type: research